Nonclinical precedent Request an invite
Atlas/Monoclonal antibodies

FDA-approved monoclonal antibodies

Single-target therapeutic antibodies and antibody fragments: checkpoint inhibitors, anti-cytokine, anti-CD20, anti-CGRP and more. 117 approved products. Click any cell to read the regulator's sentence.

Check my plan against these

Longest pivotal study, every precedent

Hover a dot · click to open · striped = derived from dosing schedule
0413263952 wk+3+56+3
ConductedConductedPartial / alternativePartial / payload / alternativeNot conductedNot conductedNot statedNot stated
117 of 117 shown
Open
Actemratocilizumab · IL-6R →
Adakveocrizanlizumab · P-selectin →
Adbrytralokinumab · IL-13 →
Aduhelmaducanumab · Aggregated amyloid-β →
Aimovigerenumab · CGRP receptor →
Ajovyfremanezumab · CGRP →
Alhemoconcizumab · TFPI →
Andembrygaradacimab · Factor XIIa →
Anthimobiltoxaximab · B. anthracis PA →
Arzerraofatumumab · CD20 →
Avastinbevacizumab · VEGF-A →
Bavencioavelumab · PD-L1 →
Benlystabelimumab · BLyS (BAFF) →
Beovubrolucizumab · VEGF-A →
Beyfortusnirsevimab · RSV F protein →
Bimzelxbimekizumab · IL-17A/IL-17F →
Briumviublituximab · CD20 →
Cablivicaplacizumab · von Willebrand factor (A1 domain) →
Campathalemtuzumab · CD52 →
Cimziacertolizumab pegol · TNF-α →
Cinqairreslizumab · IL-5 →
Cosentyxsecukinumab · IL-17A →
Crysvitaburosumab · FGF23 →
Cyramzaramucirumab · VEGFR2 →
Danyelzanaxitamab · GD2 →
Darzalexdaratumumab · CD38 →
Dupixentdupilumab · IL-4Ra →
Ebangaansuvimab · Zaire ebolavirus glycoprotein →
Ebglysslebrikizumab · IL-13 →
Emgalitygalcanezumab · CGRP →
Emplicitielotuzumab · SLAMF7 →
Enflonsiaclesrovimab · RSV F protein (site IV) →
Enjaymosutimlimab · Complement C1s →
Enspryngsatralizumab · IL-6R →
Entyviovedolizumab · α4β7-integrin →
Erbituxcetuximab · EGFR →
Evenityromosozumab · Sclerostin →
Evkeezaevinacumab · ANGPTL3 →
Exdensurdepemokimab · IL-5 →
Fasenrabenralizumab · IL-5Rα →
Gamifantemapalumab · IFN-γ →
Gazyvaobinutuzumab · CD20 →
Herceptintrastuzumab · HER2 →
Humiraadalimumab · TNF-α →
Hympavzimarstacimab · TFPI →
Ilariscanakinumab · IL-1β →
Ilumyatildrakizumab · IL-23 p19 →
Imaavynipocalimab · FcRn →
Imfinzidurvalumab · PD-L1 →
Imjudotremelimumab · CTLA-4 →
Jemperlidostarlimab · PD-1 →
Kevzarasarilumab · IL-6R →
Keytrudapembrolizumab · PD-1 →
Kisunladonanemab · Amyloid-β (N3pG) →
Lartruvoolaratumab · PDGFRα →
Leqembilecanemab · Amyloid-β protofibrils →
Libtayocemiplimab · PD-1 →
Loqtorzitoripalimab · PD-1 →
Lucentisranibizumab · VEGF-A →
Margenzamargetuximab · HER2 →
Monjuvitafasitamab · CD19 →
Nemluvionemolizumab · IL-31RA →
Niktimvoaxatilimab · CSF-1R →
Nucalamepolizumab · IL-5 →
Ocrevusocrelizumab · CD20 →
Omvohmirikizumab · IL-23 p19 →
Opdivonivolumab · PD-1 →
Pasatrugaretosmab · Activin A →
Penpulimabpenpulimab · PD-1 →
Perjetapertuzumab · HER2 →
Piaskycrovalimab · Complement C5 →
Portrazzanecitumumab · EGFR →
Poteligeomogamulizumab · CCR4 →
Praluentalirocumab · PCSK9 →
Praxbindidarucizumab · Dabigatran →
Proliadenosumab · RANKL →
Raxibacumabraxibacumab · B. anthracis protective antigen →
Remicadeinfliximab · TNF-α →
Repathaevolocumab · PCSK9 →
Rituxanrituximab · CD20 →
Rystiggorozanolixizumab · FcRn →
Saphneloanifrolumab · IFNAR1 →
Sarclisaisatuximab · CD38 →
Siliqbrodalumab · IL-17RA →
Simponigolimumab · TNF-α →
Simulectbasiliximab · IL-2Rα (CD25) →
Skyrizirisankizumab · IL-23 p19 →
Soliriseculizumab · Complement C5 →
Spevigospesolimab · IL-36R →
Stelaraustekinumab · IL-12/23 p40 →
Sylvantsiltuximab · IL-6 →
Synagispalivizumab · RSV F protein →
Takhzyrolanadelumab · Plasma kallikrein →
Taltzixekizumab · IL-17A →
Tecentriqatezolizumab · PD-L1 →
Tepezzateprotumumab · IGF-1R →
Tevimbratislelizumab · PD-1 →
Tezspiretezepelumab · TSLP →
Tremfyaguselkumab · IL-23 p19 →
Trogarzoibalizumab · CD4 →
Tysabrinatalizumab · α4-integrin →
Tzieldteplizumab · CD3 →
Ultomirisravulizumab · Complement C5 →
Unituxindinutuximab · GD2 →
Unloxcytcosibelimab · PD-L1 →
Upliznainebilizumab · CD19 →
Vectibixpanitumumab · EGFR →
Veopozpozelimab · Complement C5 →
Voyxactsibeprenlimab · APRIL →
Vyeptieptinezumab · CGRP →
Vyloyzolbetuximab · Claudin 18.2 →
Xolairomalizumab · IgE →
Yartemleanarsoplimab · MASP-2 →
Yervoyipilimumab · CTLA-4 →
Zinbrytadaclizumab · IL-2Rα (CD25) →
Zinplavabezlotoxumab · C. difficile toxin B →
Zynyzretifanlimab · PD-1 →